DOI: https://doi.org/10.22263/2312-4156.2019.2.88
Yankouskaya A.H.
Associations between the levels of estradiol, progesterone, prolactin and treatment response and quality of life in women with the first psychotic episode
Grodno State Medical University, Grodno, Republic of Belarus
Vestnik VGMU. 2019;18(2):88-95.
Abstract.
Objectives. To determine the associations between treatment response, quality of life and the level of estradiol, progesterone, prolactin in women with the first psychotic episode (FPE).
Material and methods. The study design is prospective, comparative, «case – control». The study included 98 women aged from 18 to 35 years: 55 patients with the FPE, 43 healthy women. The response to pharmacotherapy was determined by the degree of reduction of positive and negative symptoms within 4 weeks of observation. Quality of life was assessed using the Russian version of the MOS SF-36 questionnaire. Quantitative determination of blood serum hormones level was carried out by enzyme immunoassay.
Results. At the reproductive age in women with the normal menstrual cycle with the FPE compared to the control group, an increased level of prolactin was found, regardless of the phase of the menstrual cycle, and a reduced level of progesterone in the luteal phase. The comparison of female patients by the severity of psychopathological symptoms depending on the phase of the menstrual cycle showed a greater expressiveness of delusional symptoms in patients during the follicular phase. No statistically significant association was found between the degree of reduction of psychopathological symptoms during 4 weeks of observation and the blood serum concentration of prolactin, progesterone and estradiol in patients with FPE. The groups of patients with different levels of reduction of psychopathological symptoms did not differ in terms of quality of life. A negative association between the physical component of quality of life and the prolactin level was obtained.
Conclusions. At the beginning of treatment, female patients with FPE during the follicular phase of the menstrual cycle demonstrated more pronounced delusional symptoms in comparison with patients during the luteal phase. In the examined female patients, the effectiveness of antipsychotic therapy in the short term is not related to the peripheral level of sex hormones and prolactin, however, an increased prolactin level contributes to a decrease in the quality of life of patients with FPE.
Key words: first psychotic episode, treatment response, quality of life, prolactin, estradiol, progesterone.
References
1. Fusar-Poli P, McGorry PD, Kane JM. Improving outcomes of first-episode psychosis: an overview. World Psychiatry. 2017 Oct;16(3):251-265. doi: http://dx.doi.org/10.1002/wps.20446
2. Lambert M, Naber D. Current schizophrenia. 3nd ed. London: Current Medicine Group; 2012. XIV, 193 p. doi: http://dx.doi.org/10.1007/978-1-908517-68-5
3. Gorobets LN. General issues of diagnosis and prevention of neuroendocrine dysfunction in mentally ill patients. Farmateka. 2013;(16):88-91. (In Russ.)
4. Gogos A, Sbisa AM, Sun J, Gibbons A, Udawela M, Dean B. A Role for estrogen in schizophrenia: clinical and preclinical findings. Inter J Endocrinol. 2015. Available from: https://www.hindawi.com/journals/ije/2015/615356/. doi: http://dx.doi.org/10.1155/2015/615356
5. González-Rodríguez A, Catalán R, Penadés R, Ruiz Cortés V, Torra M, Seeman MV, et al. Antipsychotic response worsens with postmenopausal duration in women with schizophrenia. J Clin Psychopharmacol. 2016 Dec;36(6):580-587.
6. Kulkarni J, Gavrilidis E, Wang W, Worsley R, Fitzgerald PB, Gurvich C, et al. Estradiol for treatment-resistant schizophrenia: a large-scale randomized-controlled trial in women of child-bearing age. Mol Psychiatry. 2015 Jun;20(6):695-702. doi: http://dx.doi.org/10.1038/mp.2014.33
7. Riecher-Rössler A. Oestrogens, prolactin, hypothalamic-pituitary-gonadal axis, and schizophrenic psychoses. Lancet Psychiatry. 2017 Jan;4(1):63-72. doi: http://dx.doi.org/10.1016/S2215-0366(16)30379-0
8. Sun J, Walker AJ, Dean B, van den Buuse M, Gogos A. Progesterone: the neglected hormone in schizophrenia? A focus on progesterone-dopamine interactions. Psychoneuroendocrinology. 2016 Dec;74:126-140. doi: http://dx.doi.org/10.1016/j.psyneuen.2016.08.019
9. Seeman MV, Seeman P. Is schizophrenia a dopamine supersensitivity psychotic reaction? Prog Neuropsychopharmacol Biol Psychiatry. 2014 Jan;48:155-60. doi: http://dx.doi.org/10.1016/j.pnpbp.2013.10.003
10. Peuskens J, Pani L, Detraux J, De Hert M. The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review. CNS Drugs. 2014 May;28(5):421-53. doi: http://dx.doi.org/10.1007/s40263-014-0157-3
11. Grigg J, Worsley R, Thew C, Gurvich C, Thomas N, Kulkarni J. Antipsychotic-induced hyperprolactinemia: synthesis of world-wide guidelines and integrated recommendations for assessment, management and future research. Psychopharmacology (Berl). 2017 Nov;234(22):3279-3297. doi: http://dx.doi.org/10.1007/s00213-017-4730-6
12. Mosolov SN. Scales for psychometric assessment of schizophrenia symptoms and the concept of positive and negative disorders. Moscow, RF: Novyi svet; 2001. 238 р. (In Russ.)
13. Novik AA, Ionova TI. Guidelines no on quality of life research in medicine. Moscow, RF: OLMAPRESS; 2007. 313 р. (In Russ.)
14. Smulevich AB. Depression in general medicine: ruk dlia vrachei. Moskva, RF: MIA; 2001. 782 р. (In Russ.)
15. Boter H, Peuskens J, Libiger J, Fleischhacker WW, Davidson M, Galderisi S, et al. Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: An open randomized clinical trial (EUFEST). Schizophr Res. 2009 Dec;115(2-3):97-103. doi: http://dx.doi.org/10.1016/j.schres.2009.09.019
Information about authors:
Yankouskaya A.H. – senior lecturer of the Chair of Psychiatry and Narcology, Grodno State Medical University.
Correspondence address: Republic of Belarus, 230009, Grodno, 15/1 Obukhov str., Grodno State Medical University, Chair of Psychiatry and Narcology. E-mail: Этот адрес электронной почты защищён от спам-ботов. У вас должен быть включен JavaScript для просмотра. – Aliaksandra H. Yankouskaya.
